OverviewChartProfileKey statisticsFinancialsTechnicalNewsTraderScreen

GALENICA N/  CH0360674466  /

SIX Swiss Exchange
1/27/2023  4:03:02 PM Chg. -0.60 Volume Bid4:03:19 PM Ask4:03:19 PM Market Capitalization Dividend Y. P/E Ratio
72.40CHF -0.82% 52,810
Turnover: 3.84 mill.		 72.40Bid Size: 54 72.45Ask Size: 63 3.6 bill.CHF 2.90% 21.43
pressetext 12/19/2022 PTA-News: Biofrontera AG: Commercial launch of Ameluz® in Finland
pressetext 8/18/2022 PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 20...
pressetext 11/17/2021 PTA-News: Biofrontera AG: Biofrontera reports financial results for the third quarter and nine month...
GlobeNewswire 11/17/2021 Biofrontera reports financial results for the third quarter and nine months ended September 30, 2021
GlobeNewswire 8/19/2021 Biofrontera reports financial results for the six months ended June 30, 2021
pressetext 8/19/2021 PTA-News: Biofrontera AG: Biofrontera reports financial results for the six months ended June 30, 20...
pressetext 7/6/2021 PTA-News: Biofrontera AG: Biofrontera reports preliminary revenue for the month of June 2021
GlobeNewswire 7/6/2021 Biofrontera reports preliminary revenue for the month of June 2021
GlobeNewswire 4/12/2021 Biofrontera reports results for the 2020 financial year
pressetext 4/12/2021 PTA-News: Biofrontera AG: Biofrontera reports results for the 2020 financial year
pressetext 12/7/2020 PTA-News: Biofrontera AG: Biofrontera enters into a license and supply agreement with Galenica AB fo...
GlobeNewswire 12/7/2020 Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz®...
GlobeNewswire 9/10/2020 Opthea Appoints US-Based Non-Executive Director
GlobeNewswire 5/21/2020 Atreca Announces Appointment of Kristine M. Ball to its Board of Directors
GlobeNewswire 7/11/2019 Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer...
GlobeNewswire 6/18/2019 Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance O...
GlobeNewswire 8/28/2018 VIFOR PHARMA ISSUES INAUGURAL CHF 465 MILLION BOND
GlobeNewswire 6/25/2018 NodThera secures £28 million ($40 million) Series A Financing
GlobeNewswire 5/23/2018 Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensin...
GlobeNewswire 5/23/2018 VFMCRP AND CARA THERAPEUTICS TO DEVELOP AND COMMERCIALISE CR845 INJECTION FOR CHRONIC KIDNEY DISEASE...
GlobeNewswire 5/15/2018 90TH VIFOR PHARMA GROUP ANNUAL SHAREHOLDER MEETING
GlobeNewswire 5/15/2018 90TH VIFOR PHARMA GROUP ANNUAL SHAREHOLDER MEETING
GlobeNewswire 5/8/2018 Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa®...
GlobeNewswire 5/8/2018 US FDA APPROVES USE OF VELTASSA® WITH OR WITHOUT FOOD
GlobeNewswire 4/16/2018 Relypsa Funds Three Innovative Research Projects on Hyperkalemia and Associated Disorders